

CLAIMS

1. A molecular kinetics evaluation method comprising:
a step of evaluating molecular kinetics of a specific protein affinity molecule or a protein-degradation inducing molecule by detecting degradation of a specific protein in a specimen, wherein the molecular kinetics is specificity to tissues or organs,
wherein the specimen is collected from a human or a non-human animal which has been administered with the protein-degradation inducing molecule, which is a conjugate of a protein-degradation inducing tag as a molecule which has an affinity with a 26S proteasome and does not inhibit degradation of a protein by the 26S proteasome and the specific protein affinity molecule which has an affinity with the specific protein, and in the living body of which the degradation of the specific protein has been induced.
2. The molecular kinetics evaluation method according to claim 1, wherein in the living body of a human or a non-human animal which has been administered with the protein-degradation inducing molecule, the degradation of the specific protein is induced in a ubiquitin-independent manner.

3. The molecular kinetics evaluation method according to claim 1, wherein the protein-degradation inducing tag has a structure where a proteasome inhibitory activity of a proteasome inhibitor is inactivated.

4. The molecular kinetics evaluation method according to claim 3, wherein the proteasome inhibitory activity is an inhibitory activity against at least one selected from a caspase-like activity, a trypsin-like activity, and a chymotrypsin-like activity.

5. The molecular kinetics evaluation method according to any one of claims 1 to 4, wherein the protein-degradation inducing molecule is a drug candidate molecule, the method further comprising a step of evaluating a pharmacological action due to induction of degradation of the specific protein in the living body of a human or non-human animal.

6. A screening method comprising:
a step of selecting a specific protein affinity molecule

or a protein-degradation inducing molecule showing specific molecular kinetics by detecting degradation of a specific protein in a specimen, wherein the molecular kinetics is specificity to tissues or organs, wherein the specimen is collected from a human or a non-human animal which has been administered with the protein-degradation inducing molecule, which is a conjugate of a protein-degradation inducing tag as a molecule which has an affinity with a 26S proteasome and does not inhibit degradation of a protein by the 26S proteasome, and the specific protein affinity molecule which has an affinity with the specific protein, and in the living body of which the degradation of the specific protein has been induced.

7. The screening method according to claim 6, wherein in the living body of a human or a non-human animal which has been administered with the protein degradation inducing molecule, the degradation of the specific protein is induced in a ubiquitin-independent manner.